Tissue Transglutaminase Constitutively Activates HIF-1α Promoter and Nuclear Factor-κB via a Non-Canonical Pathway

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Kumar, Santosh ^a   Mehta, Kapil ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PARTHENOLIDE; PROTEASOME; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIUM CELL; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; ONCOGENE; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SNAIL GENE; TRANSCRIPTION REGULATION; TWIST GENE; ZEB1 GENE; ZEB2 GENE;

BIOCATALYSIS; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; CROSS-LINKING REAGENTS; DOWN-REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; I-KAPPA B KINASE; I-KAPPA B PROTEINS; MODELS, BIOLOGICAL; NF-KAPPA B; PROMOTER REGIONS, GENETIC; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEOLYSIS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSGLUTAMINASES;

GASTROPODA;

EID: 84869760482     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049321     Document Type: Article

References (48)

1. Longley DB, Johnston PG, (2005) Molecular mechanisms of drug resistance. J Pathol 205: 275-292.
2. Arlt A, Schäfer H, (2002) NF kappa B-dependent chemoresistance in solid tumors. Int J Clin Pharmacol Ther 40: 336-347.
3. Wu K, Bonavida B, (2009) The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Crit Rev Immunol 29: 241-254.
4. Nakanishi C, Toi M, (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5: 297-309.
5. Prasad S, Ravindran J, Aggarwal BB, (2010) NF-kappaB and cancer: how intimate is this relationship? Mol Cell Biochem 336: 25-37.
6. Enzler T, Sano Y, Choo M-K, Cottam HB, Karin M, et al. (2011) Cell-selective inhibition of NF-κB signaling improves therapeutic index in a melanoma chemotherapy model. Cancer Discovery 1: 496-507.
7. Mehta K, (2005) Mammalian transglutaminases: a family portrait. Prog Exp Tumor Res 38: 1-18.
8. Fesus L, Piacentini M, (2002) Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 27: 534-539.
9. Mehta K, Kumar A, Kim HI, (2010) Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer. Biochem Pharmacol 80: 1921-1929.
10. Verma A, Wang H, Manavathi B, Fok JY, Mann A, et al. (2006) Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res 66: 10525-10533.
11. Yuan L, Behdad A, Siegel M, Khosla C, Higashikubo R, et al. (2008) Tissue transgluaminase 2 expression in meningiomas. J Neuro-Oncol 90: 125-132.
12. Park KS, Kim HK, Lee JH, Choi YB, Park SY, et al. (2010) Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer. J Cancer Res Clin Oncol 136: 493-502.
13. Satpathy M, Cao L, Pincheira R, Emerson R, Bigsby R, et al. (2011) Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Res 67: 7194-7202.
14. Mehta K, Fok J, Miller FR, Koul D, Sahin AA, (2004) Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 10: 8068-8076.
15. Budillon A, Carbone C, Gennaro ED, (2011) Tissue transglutaminase: a new target to reverse cancer drug resistance. Amino Acids DOI10.007/s00726-011-1167-9.
16. Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K, (2007) Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 26: 2459-70.
17. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, et al. (2008) Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res 68: 5849-5858.
18. Satpathy M, Cao L, Pincheira R, Emerson R, Bigsby R, et al. (2007) Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Res 67: 7194-7202.
19. Oh K, Ko E, Kim HS, Park AK, Moon H-G, et al. (2011) Transglutaminase 2 facilitates the distant hematogenous metastasis of breast cancer by modulating interleukin-6 in cancer cells. Breast Cancer Res 13: R96.
20. Kumar A, Xu j, Brady S, Gao H, Yu D, et al. (2010) Tissue Transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One 5: e13390.
21. Thiery JP, Acloque H, Huang RY, Nieto MA, (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-887.
22. Kalluri R, (2009) EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 119: 1417-1419.
23. Shao M, Cao L, Shen C, Satpathy M, Chelladurai B, et al. (2009) Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res 69: 9192-9201.
24. Kumar A, Xu J, Sung B, Kumar S, Yu D, et al. (2012) Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells. Breast Cancer Res 14: R4.
25. Kumar S, Mehta K, (2011) Tissue transglutaminase, inflammation, and cancer: how intimate is the relationship? Amino Acids DOI 10.1007/s00726-011-1139-0.
26. Ben-Neriah Y, Karin M, (2011) Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol 12: 715-723.
27. Baker RG, Hayden MS, Ghosh S, (2011) NF-κB, inflammation, and metabolic disease. Cell Metab 13: 11-22.
28. Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, et al. (2004) NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression,. J Clin Invest 114: 569-581.
29. Chua P, Bhat-Nakshatri SE, Clare A, Badve MS, Nakshatri H, (2007) NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 26: 711-724.
30. Mann AP, Verma A, Sethi G, Manavathi B, Wang H, et al. (2006) Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res 66: 8788-8795.
31. Kim DS, Park SS, Nam BH, Kim IH, Kim SY, (2006) Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res 66: 10936-10943.
32. Verma A, Mehta K, (2007) Transglutaminase-mediated activation of nuclear transcription factor-kappaB in cancer cells: a new therapeutic opportunity. Curr Cancer Drug Targets 7: 559-65.
33. Park KS, Kim DS, Jeong KC, Kim SY, (2009) Increase in transglutaminase 2 expression is associated with NF-kappaB activation in breast cancer tissues. Front Biosci 4: 1945-1951.
34. Lee J, Kim YS, Choi DS, Bang MS, Han TR, et al. (2004) Transglutaminase 2 induces nuclear factor kappaB activation via a novel pathway in BV-2 microglia. J Biol Chem 279: 53725-53735.
35. Pinkas DM, Strop P, Brunger AT, Khosla C, (2007) Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol 5: e327.
36. Van Uden P, Kenneth NS, Rocha S, (2008) Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J 412: 477-484.
37. Bonello S, Zahringer C, BelAiba RS, Djordjevic T, Hess J, et al. (2007) Reactive oxygen species activate the HIF1α promoter via a functional NFkB site. Arterioscler Thromb Vasc Biol 27: 755-761.
38. Radisky DC, LaBarge MA, (2008) Epithelial-mesenchymal transition and the stem cell phenotype. Cell Stem Cell 2: 511-2.
39. Battula VL, Evans KW, Hollier BG, Shi Y, Marini FC, et al. (2010) Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells 28: 1435-1445.
40. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, et al. (2010) Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci 107: 15449-15454.
41. Cao L, Shao M, Schilder J, Guise T, Mohammad KS, et al. (2011) Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene 31: 2521-2534.
42. Cao L, Petrusca DN, Satpathy M, Nakshatri H, Petrache I, et al. (2008) Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis 29: 1893-1900.
43. Solinas G, Marchesi F, Garlanda C, Mantovani A, Allavena P, (2010) Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev 29: 243-248.
44. Yuan L, Holmes TC, Watts RE, Khosla C, Broekelmann TJ, et al. (2011) Novel chemo-sensitizing agent, ERW1227B, impairs cellular motility and enhances cell death in glioblastomas. J Neuro-Oncol 103: 207-219.
45. Jung HJ, Chen Z, Wang M, Fayad L, Romaguera J, et al. (2012) Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma (MCL) via manipulation of tissue transglutaminase activities. Blood 2012; PMID:22294726.
46. Zhang L, Ding X, Cui J, Xu H, Chen J, et al. (2012) Cysteine methylation disrupts ubiquitin-chain sensing in NF-κB activation. Nature 481: 204-208.
47. Wilson WR, Hay MP, (2011) Targeting hypoxia in cancer therapy. Nat Rev Cancer 11: 393-410.
48. Kim DS, Choi YB, Han BG, Park SY, Jeon Y, et al. (2011) Cancer cells promote survival through depletion of the von Hippel-Lindau tumor suppressor by protein crosslinking. Oncogene 30: 4780-4790.